May 8 P&P Quick Takes: FTC, Part D, Orange/Purple Book, FDA, Cornyn/Blumenthal

FTC objects to FDA's latest guidance on biologic naming
The Federal Trade Commission again advised that FDA drop its biologic suffix naming convention because it could diminish biosimilar competition, bolstering arguments from some biosimilars